Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Immuneering Corporation (Nasdaq: IMRX) recently announced its participation in the 22^nd Annual Needham Virtual Healthcare Conference on April 19, 2023, from 12:45 - 1:25 pm ET. The presentation will provide insights into the company's pipeline, platform, and business strategy.

Key management participating includes Ben Zeskind, CEO; Scott Barrett, CMO; Brett Hall, CSO; and Mallory Morales, VP of Finance. The event will feature a virtual presentation followed by 1x1 investor meetings. All presentations will be webcast live and archived for 30 days on Immuneering's website.

Immuneering is focused on developing medicines for cancer patients, particularly aiming for a universal-RAS therapy through deep cyclic inhibition of the MAPK pathway. Its lead candidate, IMM-1-104, is currently in Phase 1/2a trials for RAS mutation-related advanced solid tumors.

CAMBRIDGE, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the 22^nd Annual Needham Virtual Healthcare Conference to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Scott Barrett, M.D., Chief Medical Officer, Brett Hall, Ph.D., Chief Scientific Officer, and Mallory Morales, CPA, Vice President of Finance, Treasurer.

Format: Virtual Presentation and 1x1 Investor Meetings
Virtual Presentation: April 19 from 12:45 - 1:25 pm ET in Track 1

The presentations will be webcast live and archived for 30 days in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.

About Immuneering Corporation  

Immuneering is a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The company aims to achieve universal activity through deep cyclic inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering’s lead product candidate, IMM-1-104, is in a Phase 1/2a study in patients with advanced solid tumors harboring RAS mutations. The company’s development pipeline also includes IMM-6-415, a universal-MAPK program, as well as several early-stage programs. For more information, please visit www.immuneering.com.  

Media Contact:
Gina Nugent 
Nugent Communications 
617-460-3579 
gina@nugentcommunications.com

Investor Contacts: 
Laurence Watts 
Gilmartin Group 
619-916-7620 
laurence@gilmartinir.com

or

Kiki Patel, PharmD 
Gilmartin Group 
332-895-3225
kiki@gilmartinir.com

FAQ

When is Immuneering's presentation at the Needham Virtual Healthcare Conference?

Immuneering Corporation will present on April 19, 2023, from 12:45 - 1:25 pm ET.

Who will represent Immuneering at the conference?

Ben Zeskind (CEO), Scott Barrett (CMO), Brett Hall (CSO), and Mallory Morales (VP of Finance) will represent Immuneering.

What is the focus of Immuneering's clinical development?

Immuneering focuses on developing therapies for cancer patients, specifically targeting a universal-RAS therapy and deep cyclic inhibition of the MAPK pathway.

What is the lead product candidate of Immuneering?

Immuneering's lead product candidate is IMM-1-104, currently in a Phase 1/2a study for advanced solid tumors with RAS mutations.

Where can I watch Immuneering's presentation?

The presentation will be webcast live and archived for 30 days on Immuneering's website in the Investor Relations section.